NO933394L - Omformede monoklonale antistoffer mot en immunoglobulin isotype - Google Patents

Omformede monoklonale antistoffer mot en immunoglobulin isotype

Info

Publication number
NO933394L
NO933394L NO933394A NO933394A NO933394L NO 933394 L NO933394 L NO 933394L NO 933394 A NO933394 A NO 933394A NO 933394 A NO933394 A NO 933394A NO 933394 L NO933394 L NO 933394L
Authority
NO
Norway
Prior art keywords
monoclonal antibodies
converted
immunoglobulin isotype
immunoglobulin
isotype
Prior art date
Application number
NO933394A
Other languages
English (en)
Other versions
NO318210B1 (no
NO933394D0 (no
Inventor
Norman Hardman
Frank Kolbinger
Jose Saldanha
Original Assignee
Ciba Geigy Ag
Tanox Biosystems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929220228A external-priority patent/GB9220228D0/en
Application filed by Ciba Geigy Ag, Tanox Biosystems Inc filed Critical Ciba Geigy Ag
Publication of NO933394D0 publication Critical patent/NO933394D0/no
Publication of NO933394L publication Critical patent/NO933394L/no
Publication of NO318210B1 publication Critical patent/NO318210B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6873—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an immunoglobulin; the antibody being an anti-idiotypic antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO19933394A 1992-09-24 1993-09-23 Omformede monoklonale antistoffer mot en immunoglobulin isotype, konjugat, fremgangsmate, DNA, hybridvektor, vertscelleanvendelse, farmasoytisk sammensetning og testkit derav. NO318210B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929220228A GB9220228D0 (en) 1992-09-24 1992-09-24 Reshaped monoclonal antibodies against an immunologlobulin isotype
US95280292A 1992-09-25 1992-09-25

Publications (3)

Publication Number Publication Date
NO933394D0 NO933394D0 (no) 1993-09-23
NO933394L true NO933394L (no) 1994-03-25
NO318210B1 NO318210B1 (no) 2005-02-21

Family

ID=26301683

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19933394A NO318210B1 (no) 1992-09-24 1993-09-23 Omformede monoklonale antistoffer mot en immunoglobulin isotype, konjugat, fremgangsmate, DNA, hybridvektor, vertscelleanvendelse, farmasoytisk sammensetning og testkit derav.

Country Status (18)

Country Link
EP (2) EP1452542A3 (no)
JP (2) JP3636737B2 (no)
KR (1) KR100298608B1 (no)
CN (2) CN1078250C (no)
AT (1) ATE264388T1 (no)
AU (1) AU675449B2 (no)
CA (1) CA2106719C (no)
CY (1) CY2583B2 (no)
DE (1) DE69333484T2 (no)
DK (1) DK0589840T3 (no)
ES (1) ES2219640T3 (no)
FI (2) FI114550B (no)
HK (1) HK1056182A1 (no)
IL (2) IL107049A (no)
MX (1) MX9305920A (no)
NO (1) NO318210B1 (no)
NZ (1) NZ248743A (no)
PT (1) PT589840E (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA966075B (en) * 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
AU7156996A (en) * 1995-09-13 1997-04-01 Genentech Inc. Methods for treatment of interstitial cystitis
US6127524A (en) * 1996-10-18 2000-10-03 Dade Behring Inc. Binding molecules and computer-based methods of increasing the binding affinity thereof
EP1056471A4 (en) * 1998-01-29 2001-05-30 Tanox Inc TREATMENT OF ATOPIC DERMATITIS USING IgE ANTAGONISTS
BRPI0316092B8 (pt) * 2002-11-08 2021-05-25 Ablynx Nv anticorpos de domínio único direcionados contra o fator de necrose tumoral alfa e usos para os mesmos
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
EP2336179A1 (en) 2002-11-08 2011-06-22 Ablynx N.V. Stabilized single domain antibodies
CN1829806A (zh) * 2003-02-01 2006-09-06 唐纳士公司 产生高亲和力抗体的方法
AU2004315197B2 (en) * 2004-02-02 2009-06-04 Tanox, Inc. Identification of novel IgE epitopes
CA2738243C (en) 2008-10-29 2020-09-29 Wyeth Llc Formulations of single domain antigen binding molecules
CA2739352C (en) 2008-10-29 2021-07-13 Wyeth Llc Methods for purification of single domain antigen binding molecules

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0407392B2 (en) * 1987-12-31 1998-10-28 Tanox Biosystems, Inc. UNIQUE ANTIGENIC EPITOPES ON IgE-BEARING B LYMPHOCYTES
US5104604A (en) * 1989-10-05 1992-04-14 Dexter Electronic Materials Div. Of Dexter Corp. Flame retardant epoxy molding compound, method and encapsulated device method of encapsulating a semiconductor device with a flame retardant epoxy molding compound
JP2988635B2 (ja) * 1990-09-18 1999-12-13 塩野義製薬株式会社 ヒトＩｇＥに対するモノクローナル抗体
WO1992017207A1 (en) * 1991-03-26 1992-10-15 Tanox Biosystems, Inc. MONOCLONAL ANTIBODIES WHICH BIND TO SECRETED AND MEMBRANE-BOUND IgE, BUT NOT TO IgE ON BASOPHILS
ES2193136T3 (es) * 1991-08-14 2003-11-01 Genentech Inc Variantes de inmunoglubina para receptores especificos de fc epsilon.

Also Published As

Publication number Publication date
ATE264388T1 (de) 2004-04-15
FI934145A0 (fi) 1993-09-22
DE69333484D1 (de) 2004-05-19
EP0589840A1 (en) 1994-03-30
ES2219640T3 (es) 2004-12-01
IL107049A0 (en) 1993-12-28
EP1452542A2 (en) 2004-09-01
IL107049A (en) 2006-07-05
CN1088986A (zh) 1994-07-06
KR100298608B1 (ko) 2001-11-22
AU675449B2 (en) 1997-02-06
JPH06225788A (ja) 1994-08-16
JP3636737B2 (ja) 2005-04-06
CN1428352A (zh) 2003-07-09
CN1078250C (zh) 2002-01-23
FI114550B (fi) 2004-11-15
FI115838B (fi) 2005-07-29
FI934145A (fi) 1994-03-25
CA2106719A1 (en) 1994-03-25
DE69333484T2 (de) 2005-03-24
IL173988A0 (en) 2006-07-05
MX9305920A (es) 1994-05-31
JP3718214B2 (ja) 2005-11-24
CA2106719C (en) 2006-03-28
NO318210B1 (no) 2005-02-21
KR940006602A (ko) 1994-04-25
EP1452542A3 (en) 2007-05-02
AU4748893A (en) 1994-03-31
CY2583B2 (en) 2009-11-04
FI20040696A (fi) 2004-05-19
NO933394D0 (no) 1993-09-23
EP0589840B1 (en) 2004-04-14
CN1254487C (zh) 2006-05-03
HK1056182A1 (en) 2004-02-06
NZ248743A (en) 1995-04-27
JP2004357712A (ja) 2004-12-24
PT589840E (pt) 2004-08-31
DK0589840T3 (da) 2004-07-26

Similar Documents

Publication Publication Date Title
CY2583B2 (en) Reshaped monoclonal antibodies against an immunoglobulin isotype
ATE512224T1 (de) Rekonstituierter menschlicher anti-hm.1 antikörper
NO2017040I1 (no) Natalizumab, anti alfa-4 integrin humanisert monoklonalt antistoff - forlenget SPC
DK0758904T3 (da) Fremgangsmåder og sammensætninger til behandling af glomerulonephritis
ATE233814T1 (de) Humaner neutralisierender monoklonaler antikörper gegen den die immunschwäche beim menschen hervorringenden virus
ATE347565T1 (de) Bispezifischer antikörper zur effektiven behandlung von b-zell lymphomen und zellinien
WO2004070010A3 (en) A method for generating high affinity antibodies
DE69434097D1 (de) Apoptose induzierender monoklonaler antikörper
ATE166230T1 (de) Verwendung von anti-icam antikörpern zur herstellung eines präparats für die behandlung von endotoxinschock
MX9301858A (es) Anticuerpos monoclonales neutralizantes de hiv-humano recombinante para prevencion y tratamiento de infeccion hiv.
EA200200974A1 (ru) Моноклональные антитела к рецептору лпнп человека, их получение и применение
EP0396505A3 (en) Monoclonal antibodies specific for an immunoglobulin isotype
EP0554670A3 (en) Specific antibodies against activated platelets, their production and applications in diagnostics and therapeutics
RU95110653A (ru) Средство, стимулирующее в эксперименте синтез иммуноглобулинов
RU93035807A (ru) Способ лечения юношеского эпифизиолиса
DK0574461T3 (da) Humaniserede, monoklonale højaffinitetsantistoffer
SE9404491D0 (sv) Process for the production of human monoclonal antibodies

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees